Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions

voriconazole

  • <em>ERG11</em> Polymorphism in Voriconazole-Resistant <span class="named-content genus-species" id="named-content-1">Candida tropicalis</span>: Weak Role of <em>ERG11</em> Expression, Ergosterol Content, and Membrane Permeability
    Mechanisms of Resistance
    ERG11 Polymorphism in Voriconazole-Resistant Candida tropicalis: Weak Role of ERG11 Expression, Ergosterol Content, and Membrane Permeability

    Mutations in ERG11 were detected by gene sequencing and amino acid alignment in 18 Candida tropicalis strains with different degrees of sensitivity to voriconazole (VRC). ERG11 expression, sterol content, and membrane permeability were also evaluated. We report three missense mutations in ERG11 that resulted in resistance to VRC. The...

    Patricia Navarro-Rodríguez, Loida López-Fernández, Adela Martin-Vicente, Josep Guarro, Javier Capilla
  • Impact of Obesity on Voriconazole Pharmacokinetics among Pediatric Hematopoietic Cell Transplant Recipients
    Pharmacology
    Impact of Obesity on Voriconazole Pharmacokinetics among Pediatric Hematopoietic Cell Transplant Recipients

    Voriconazole (VCZ) is an antifungal agent with wide inter- and intrapatient pharmacokinetic (PK) variability and narrow therapeutic index. Although obesity was associated with higher VCZ trough concentrations in adults, the impact of obesity had yet to be studied in children. We characterized the PK of VCZ in obese patients by accounting for age and CYP2C19 phenotype. We conducted intensive PK studies of VCZ and VCZ N-oxide...

    Takuto Takahashi, Angela R. Smith, Pamala A. Jacobson, James Fisher, Nathan T. Rubin, Mark N. Kirstein
  • <span class="named-content genus-species" id="named-content-1">Aspergillus fumigatus</span> Cyp51A and Cyp51B Proteins Are Compensatory in Function and Localize Differentially in Response to Antifungals and Cell Wall Inhibitors
    Mechanisms of Resistance
    Aspergillus fumigatus Cyp51A and Cyp51B Proteins Are Compensatory in Function and Localize Differentially in Response to Antifungals and Cell Wall Inhibitors

    Triazole antifungals are the primary therapeutic option against invasive aspergillosis. However, resistance to azoles has increased dramatically over the last decade. Azole resistance is known to primarily occur due to point mutations in the azole target protein Cyp51A, one of two paralogous 14-α sterol demethylases found in Aspergillus fumigatus. Despite the...

    Mark T. Roundtree, Praveen R. Juvvadi, E. Keats Shwab, D. Christopher Cole, William J. Steinbach
  • Toward Harmonization of Voriconazole CLSI and EUCAST Breakpoints for <span class="named-content genus-species" id="named-content-1">Candida albicans</span> Using a Validated <em>In Vitro</em> Pharmacokinetic/Pharmacodynamic Model
    Editor's Pick Susceptibility
    Toward Harmonization of Voriconazole CLSI and EUCAST Breakpoints for Candida albicans Using a Validated In Vitro Pharmacokinetic/Pharmacodynamic Model

    CLSI and EUCAST susceptibility breakpoints for voriconazole and Candida albicans differ by one dilution (≤0.125 and ≤0.06 mg/liter, respectively) whereas the epidemiological cutoff values for EUCAST (ECOFF) and CLSI (ECV) are the same (0.03 mg/liter). We therefore determined the pharmacokinetic/pharmacodynamic (PK/PD) breakpoints of voriconazole against...

    Maria-Ioanna Beredaki, Panagiota-Christina Georgiou, Maria Siopi, Lamprini Kanioura, David Andes, Maiken Cavling Arendrup, Johan W. Mouton, Joseph Meletiadis
  • Mechanisms of Acquired <em>In Vivo</em> and <em>In Vitro</em> Resistance to Voriconazole by <span class="named-content genus-species" id="named-content-1">Candida krusei</span> following Exposure to Suboptimal Drug Concentration
    Mechanisms of Resistance
    Mechanisms of Acquired In Vivo and In Vitro Resistance to Voriconazole by Candida krusei following Exposure to Suboptimal Drug Concentration

    Five Candida krusei isolates (susceptible and resistant) recovered from the urine of a kidney transplant patient treated with voriconazole (VRC) 200 mg twice daily for 20 days were studied. Eight unrelated clinical isolates of C. krusei were exposed in vitro to VRC 0.001 μg/ml for 30 days....

    Elisabete Ricardo, Fréderic Grenouillet, Isabel M. Miranda, Raquel M. Silva, Guilluame Eglin, Nadège Devillard, Acácio Gonçalves Rodrigues, Cidália Pina-Vaz
  • <em>In Vitro</em> Antifungal Combination of Flucytosine with Amphotericin B, Voriconazole, or Micafungin against <span class="named-content genus-species" id="named-content-1">Candida auris</span> Shows No Antagonism
    Susceptibility
    In Vitro Antifungal Combination of Flucytosine with Amphotericin B, Voriconazole, or Micafungin against Candida auris Shows No Antagonism

    Candida auris is an emerging, multidrug-resistant pathogen responsible for invasive hospital-acquired infections. Flucytosine is an effective anti-Candida species drug, but which cannot be used as a monotherapy because of the risk of development of resistant mutants during treatment. It is, therefore, noteworthy to test possible combinations with flucytosine...

    A. L. Bidaud, F. Botterel, A. Chowdhary, E. Dannaoui
  • Open Access
    <span class="named-content genus-species" id="named-content-1">Trichophyton rubrum</span> Azole Resistance Mediated by a New ABC Transporter, TruMDR3
    Mechanisms of Resistance
    Trichophyton rubrum Azole Resistance Mediated by a New ABC Transporter, TruMDR3

    The mechanisms of terbinafine resistance in a set of clinical isolates of Trichophyton rubrum have been studied recently. Of these isolates, TIMM20092 also showed reduced sensitivity to azoles. The azole resistance of TIMM20092 could be inhibited by milbemycin oxime, prompting us to examine the potential of...

    Michel Monod, Marc Feuermann, Karine Salamin, Marina Fratti, Maya Makino, Mohamed Mahdi Alshahni, Koichi Makimura, Tsuyoshi Yamada
  • Therapeutic Challenges of Non-<em>Aspergillus</em> Invasive Mold Infections in Immunosuppressed Patients
    Editor's Pick Minireview
    Therapeutic Challenges of Non-Aspergillus Invasive Mold Infections in Immunosuppressed Patients

    While Aspergillus spp. remain the major cause of invasive mold infections in hematologic cancer patients and transplant recipients, other opportunistic molds, such as Mucorales, Fusarium, and Scedosporium spp. are increasingly encountered in an expanding population of patients with severe and prolonged immunosuppression. High potential for tissue invasion and dissemination, resistance to multiple...

    Frederic Lamoth, Dimitrios P. Kontoyiannis
  • Molecular Identification, Antifungal Susceptibility Testing, and Mechanisms of Azole Resistance in <em>Aspergillus</em> Species Received within a Surveillance Program on Antifungal Resistance in Spain
    Susceptibility
    Molecular Identification, Antifungal Susceptibility Testing, and Mechanisms of Azole Resistance in Aspergillus Species Received within a Surveillance Program on Antifungal Resistance in Spain

    Antifungal resistance is one of the major causes of the increasing mortality rates for fungal infections, especially for those caused by Aspergillus spp. A surveillance program was established in 2014 in the Spanish National Center for Microbiology for tracking resistance in the most prevalent Aspergillus species. A total of 273 samples were included in the...

    Olga Rivero-Menendez, Juan Carlos Soto-Debran, Narda Medina, Jose Lucio, Emilia Mellado, Ana Alastruey-Izquierdo
  • Genomewide Elucidation of Drug Resistance Mechanisms for Systemically Used Antifungal Drugs Amphotericin B, Caspofungin, and Voriconazole in the Budding Yeast
    Mechanisms of Resistance
    Genomewide Elucidation of Drug Resistance Mechanisms for Systemically Used Antifungal Drugs Amphotericin B, Caspofungin, and Voriconazole in the Budding Yeast

    There are only a few antifungal drugs used systemically in treatment, and invasive fungal infections that are resistant to these drugs are an emerging problem in health care. In this study, we performed a high-copy-number genomic DNA (gDNA) library screening to find and characterize genes that reduce susceptibility to amphotericin B, caspofungin, and voriconazole in ...

    Cigdem Balkan, Ilkcan Ercan, Esin Isik, Esra Sahin Akdeniz, Orhan Balcioglu, Marie Kodedová, Olga Zimmermannová, Muhammed Dundar, Hana Sychrová, Ahmet Koc

Pages

  • Next
  • 1
  • 2
  • 3
  • 4
Back to top

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596